Company Filing History:
Years Active: 2014
Title: Edward Thomas Glenn: Innovator in Selective Modulation of the CB2 Receptor
Introduction
Edward Thomas Glenn is a prominent inventor based in Abingdon, GB, known for his innovative contributions to the field of medicinal chemistry. With a focus on the modulation of the CB2 receptor, his work offers significant potential for therapeutic interventions, particularly in treating pain and inflammation.
Latest Patents
Edward Thomas Glenn holds a patent for "Compounds which selectively modulate the CB2 receptor." This patent details various compounds of formula (I) that effectively bind to and act as agonists, antagonists, or inverse agonists of the CB2 receptor. The implications of his research are extensive, offering promising treatment avenues for inflammation and pain relief.
Career Highlights
Glenn is associated with Boehringer Ingelheim International GmbH, a global leader in biopharmaceuticals. His role at the company underscores his commitment to advancing medical science and improving patient outcomes through innovative drug development.
Collaborations
Throughout his career, Edward has collaborated with other talented professionals, including Alessandra Bartolozzi and Eugene R Hickey. Together, they contribute to significant advancements in their respective fields, emphasizing teamwork in the quest for groundbreaking medical solutions.
Conclusion
Edward Thomas Glenn's inventive efforts and dedication to the modulation of the CB2 receptor reflect his passion for enhancing patient care. His work, combined with strong collaborations and a supportive company environment, paves the way for future innovations in medical treatments.